OBJECTIVE: To investigate potential differences in the availability of medicines for chronic and acute conditions in low- and middle-income countries. METHODS: Data on the availability of 30 commonly-surveyed medicines - 15 for acute and 15 for chronic conditions - were obtained from facility-based surveys conducted in 40 developing countries. Results were aggregated by World Bank country income group and World Health Organization region. FINDINGS: The availability of medicines for both acute and chronic conditions was suboptimal across countries, particularly in the public sector. Generic medicines for chronic conditions were significantly less available than generic medicines for acute conditions in both the public sector (36.0% availability versus 53.5%; P = 0.001) and the private sector (54.7% versus 66.2%; P = 0.007). Antiasthmatics, antiepileptics and antidepressants, followed by antihypertensives, were the drivers of the observed differences. An inverse association was found between country income level and the availability gap between groups of medicines, particularly in the public sector. In low- and lower-middle income countries, drugs for acute conditions were 33.9% and 12.9% more available, respectively, in the public sector than medicines for chronic conditions. Differences in availability were smaller in the private sector than in the public sector in all country income groups. CONCLUSION: Current disease patterns do not explain the significant gaps observed in the availability of medicines for chronic and acute conditions. Measures are needed to better respond to the epidemiological transition towards chronic conditions in developing countries alongside current efforts to scale up treatment for communicable diseases.
OBJECTIVE: To investigate potential differences in the availability of medicines for chronic and acute conditions in low- and middle-income countries. METHODS: Data on the availability of 30 commonly-surveyed medicines - 15 for acute and 15 for chronic conditions - were obtained from facility-based surveys conducted in 40 developing countries. Results were aggregated by World Bank country income group and World Health Organization region. FINDINGS: The availability of medicines for both acute and chronic conditions was suboptimal across countries, particularly in the public sector. Generic medicines for chronic conditions were significantly less available than generic medicines for acute conditions in both the public sector (36.0% availability versus 53.5%; P = 0.001) and the private sector (54.7% versus 66.2%; P = 0.007). Antiasthmatics, antiepileptics and antidepressants, followed by antihypertensives, were the drivers of the observed differences. An inverse association was found between country income level and the availability gap between groups of medicines, particularly in the public sector. In low- and lower-middle income countries, drugs for acute conditions were 33.9% and 12.9% more available, respectively, in the public sector than medicines for chronic conditions. Differences in availability were smaller in the private sector than in the public sector in all country income groups. CONCLUSION: Current disease patterns do not explain the significant gaps observed in the availability of medicines for chronic and acute conditions. Measures are needed to better respond to the epidemiological transition towards chronic conditions in developing countries alongside current efforts to scale up treatment for communicable diseases.
Authors: Shanti Mendis; Keiko Fukino; Alexandra Cameron; Richard Laing; Anthonio Filipe; Oussama Khatib; Jerzy Leowski; Margaret Ewen Journal: Bull World Health Organ Date: 2007-04 Impact factor: 9.408
Authors: Edward J Mills; Jean B Nachega; Iain Buchan; James Orbinski; Amir Attaran; Sonal Singh; Beth Rachlis; Ping Wu; Curtis Cooper; Lehana Thabane; Kumanan Wilson; Gordon H Guyatt; David R Bangsberg Journal: JAMA Date: 2006-08-09 Impact factor: 56.272
Authors: Ke Xu; David B Evans; Kei Kawabata; Riadh Zeramdini; Jan Klavus; Christopher J L Murray Journal: Lancet Date: 2003-07-12 Impact factor: 79.321
Authors: Catherine E Vialle-Valentin; Brian Serumaga; Anita K Wagner; Dennis Ross-Degnan Journal: Health Policy Plan Date: 2014-09-24 Impact factor: 3.344
Authors: Martin Muddu; Andrew K Tusubira; Srish K Sharma; Ann R Akiteng; Isaac Ssinabulya; Jeremy I Schwartz Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731